Amphastar Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceRANCHO CUCAMONGA, CA / ACCESSWIRE / January 8, 2025 / Amphastar Pharmaceuticals, Inc. (
NASDAQAMPH) announced today that Jack Zhang, CEO and President, and Bill Peters, CFO will be presenting at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15th, 2025, at 11:15 am PST. For access, visit Amphastar's Pharmaceuticals website at http://ir.amphastar.com. This webcast will be available for 30 days following the presentation.
Amphastar Pharmaceuticals to Present at the 36th Annual Piper Sandler Healthcare ConferenceRANCHO CUCAMONGA, CA / ACCESSWIRE / November 26, 2024 / Amphastar Pharmaceuticals, Inc. (
NASDAQAMPH) announced today that Bill Peters, CFO, and Dan Dischner SVP of Corp. Communication, will participate in an Analyst-Moderated fireside chat at the 36th Annual Piper Sandler Healthcare Conference on Wednesday, December 4th, 2024 at 11:30 am EST. For access, visit Amphastar's Pharmaceuticals website at http://ir.amphastar.com. This webcast will be available for 30 days following the presentation.
Amphastar Pharmaceuticals to Present at the Jefferies London Healthcare ConferenceRANCHO CUCAMONGA, CA / ACCESSWIRE / November 13, 2024 / Amphastar Pharmaceuticals, Inc. (
NASDAQAMPH) announced today that Bill Peters, CFO, and Jacob Liawatidewi, EVP of Corporate Administration, will participate in an Analyst-Moderated fireside chat at the Jefferies London Healthcare Conference on Wednesday, November 20, 2024 at 3:30 pm GMT. For access, visit Amphastar's Pharmaceuticals website at http://ir.amphastar.com. This webcast will be available for 30 days following the presentation.
Amphastar Pharmaceuticals to Present at the 2024 Wells Fargo Healthcare ConferenceRANCHO CUCAMONGA, CA / ACCESSWIRE / August 28, 2024 / Amphastar Pharmaceuticals, Inc. (
NASDAQAMPH) announced today that Bill Peters, CFO, and Tony Marrs, EVP of Regulatory Affairs and Clinical Operations, will participate in a fireside chat at the 2024 Wells Fargo Healthcare Conference on Thursday, September 5, 2024 at 10:15 am EST. For access, visit Amphastar's Pharmaceuticals website at http://ir.amphastar.com. This webcast will be available for 30 days following the presentation.
Amphastar Pharmaceuticals to Release Second Quarter Earnings and Hold Conference Call on August 7, 2024RANCHO CUCAMONGA, CA / ACCESSWIRE / July 31, 2024 / Amphastar Pharmaceuticals, Inc. (
NASDAQAMPH) announced that the Company will release results for its Second quarter of 2024 ended June 30, 2024, after the market closes on Wednesday, August 7, 2024, and will hold a conference call to discuss its financial results at 2:00 p.m. Pacific Time.
Top 2 Small Cap Healthcare Stocks to Buy Before Rate CutsThese 2 small cap healthcare stocks could boom on a new sector breakout, Wall Street analysts see up to double-digit upside in each
Amphastar Announces Additional $50 Million Increase to its Share Buyback ProgramRANCHO CUCAMONGA, CA / ACCESSWIRE / June 4, 2024 / Amphastar Pharmaceuticals, Inc. (
NASDAQAMPH) today announced that on June 3, 2024, the Company's Board of Directors authorized a $50 million increase to the Company's share buyback program, which is expected to continue for an indefinite period of time. The primary goal of the program is to offset dilution created by the Company's equity compensation programs.
Amphastar Pharmaceuticals to Present at the Jefferies Global Healthcare ConferenceRANCHO CUCAMONGA, CA / ACCESSWIRE / June 3, 2024 / Amphastar Pharmaceuticals, Inc. (
NASDAQAMPH) announced today that Bill Peters, CFO, and Jacob Liawatidewi, EVP of Corporate Administration, will participate in an Analyst-Moderated fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 6, 2024 at 12:30 pm EST. For access, visit Amphastar's Pharmaceuticals website at http://ir.amphastar.com. This webcast will be available for 30 days following the presentation.
Amphastar Receives FDA Approval for Albuterol Sulfate Inhalation AerosolRANCHO CUCAMONGA, CA / ACCESSWIRE / May 22, 2024 / Amphastar Pharmaceuticals, Inc. (
NASDAQAMPH) today announced that the U.S. Food and Drug Administration ("FDA") has granted approval for the Company's Abbreviated New Drug Application ("ANDA") for Albuterol Sulfate Inhalation Aerosol, previously known as AMP-008. This product is for the treatment or prevention of bronchospasm in patients four years of age and older with reversible obstructive airway disease and the prevention of exercise-induced bronchospasm in patients four years of age and older. The FDA determined that Amphastar's albuterol is bioequivalent and therapeutically equivalent to Teva Respiratory LLC's ProAir® HFA (albuterol sulfate) Inhalation Aerosol.
Amphastar Pharmaceuticals to Present at the Bank of America Securities Health Care ConferenceRANCHO CUCAMONGA, CA / ACCESSWIRE / May 9, 2024 / Amphastar Pharmaceuticals, Inc. (
NASDAQAMPH) announced today that Bill Peters, CFO, and Dan Dischner SVP of Corp. Communication, will participate in an Analyst-Moderated fireside chat at the Bank of America Health Care Conference on Wednesday, May 15th, 2024 at 2:20 pm PDT. For access, visit Amphastar's Pharmaceuticals website at http://ir.amphastar.com. This webcast will be available for 30 days following the presentation.
Amphastar Pharmaceuticals to Release First Quarter Earnings and Hold Conference Call on May 8, 2024RANCHO CUCAMONGA, CA / ACCESSWIRE / April 30, 2024 / Amphastar Pharmaceuticals, Inc. (
NASDAQAMPH) announced that the Company will release results for its first quarter of 2024 ended March 31, 2024, after the market closes on Wednesday, May 8, 2024, and will hold a conference call to discuss its financial results at 2:00 p.m. Pacific Time.
Amphastar Pharmaceuticals to Present at the 23rd Annual Needham Virtual Healthcare ConferenceRANCHO CUCAMONGA, CA / ACCESSWIRE / April 1, 2024 / Amphastar Pharmaceuticals, Inc. (
NASDAQAMPH) announced today that Bill Peters, CFO, Tony Marrs, EVP of Regulatory Affairs and Clinical Operations, and Dan Dischner SVP of Corp. Communication, will participate in an Analyst-Moderated fireside chat at the 23rd Annual Needham Virtual Healthcare Conference on April 9th, 2024 at 3:00 pm EST. For access, visit Amphastar's Pharmaceuticals website at http://ir.amphastar.com. This webcast will be available for 30 days following the presentation.
Amphastar Pharmaceuticals to Present at the Barclays 26th Annual Global Healthcare ConferenceRANCHO CUCAMONGA, CA / ACCESSWIRE / March 6, 2024 / Amphastar Pharmaceuticals, Inc. (
NASDAQAMPH) announced today that Bill Peters, CFO and Tony Marrs, EVP of Regulatory Affairs and Clinical Operations, will be presenting at the Barclays 26th Annual Global Healthcare Conference on Wednesday, March 13th, 2024 at 11:15 am EST. For access, visit Amphastar's Pharmaceuticals website at http://ir.amphastar.com. This webcast will be available for 30 days following the presentation.
Amphastar Pharmaceuticals to Release Fourth Quarter Earnings and Hold Conference Call on February 28, 2024RANCHO CUCAMONGA, CA / ACCESSWIRE / February 20, 2024 / Amphastar Pharmaceuticals, Inc. (
NASDAQAMPH) announced that the Company will release results for its fourth quarter of 2023 ended December 31, 2023, after the market closes on Wednesday, February 28, 2024, and will hold a conference call to discuss its financial results at 2:00 p.m. Pacific Time.
Amphastar Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceRANCHO CUCAMONGA, CA / ACCESSWIRE / January 2, 2024 / Amphastar Pharmaceuticals, Inc. (
NASDAQAMPH) announced today that Dr. Jack Zhang, CEO and President, and Bill Peters, CFO will be presenting at the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024 at 9:00 am PST. For access, visit Amphastar's Pharmaceuticals website at http://ir.amphastar.com. This webcast will be available for 30 days following the presentation.
Amphastar Pharmaceuticals to Present at the Piper Sandler 35th Annual Healthcare ConferenceRANCHO CUCAMONGA, CA / ACCESSWIRE / November 20, 2023 / Amphastar Pharmaceuticals, Inc. (
NASDAQAMPH) announced today that Bill Peters, CFO and Dan Dischner, S.V.P. of Corporate Communications, will participate in an Analyst-Moderated fireside chat at the Piper Sandler 35th Annual Healthcare Conference on Wednesday, November 29, 2023 at 9:30 am EST. For access, visit Amphastar's Pharmaceuticals website at http://ir.amphastar.com . This webcast will be available for 90 days following the presentation.
Amphastar Pharmaceuticals to Present at the Jefferies London Healthcare ConferenceRANCHO CUCAMONGA, CA / ACCESSWIRE / November 9, 2023 / Amphastar Pharmaceuticals, Inc. (
NASDAQAMPH) announced today that Bill Peters, CFO and Jacob Liawatidewi EVP of Corp. Administration, will participate in an Analyst-Moderated fireside chat at the Jefferies London Healthcare Conference on Wednesday, November 15, 2023 at 2:30 pm GMT. For access, visit Amphastar's Pharmaceuticals website at http://ir.amphastar.com . This webcast will be available for 90 days following the presentation.
Amphastar Pharmaceuticals to Release Third Quarter Earnings and Hold Conference Call on November 8, 2023RANCHO CUCAMONGA, CA / ACCESSWIRE / November 1, 2023 / Amphastar Pharmaceuticals, Inc. (
NASDAQAMPH) announced that the Company will release results for its third quarter of 2023 ended September 30, 2023, after the market closes on Wednesday, November 8, 2023, and will hold a conference call to discuss its financial results at 2:00 p.m. Pacific Time.
Amphastar Pharmaceuticals Announces Pricing of Offering of $300.0 Million of Convertible Senior NotesRANCHO CUCAMONGA, CA / ACCESSWIRE / September 13, 2023 / Amphastar Pharmaceuticals, Inc. (
NASDAQAMPH) ("Amphastar") today announced the pricing of $300.0 million aggregate principal amount of 2.00% convertible senior notes due 2029 (the "notes") in a private placement to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). Amphastar also granted the initial purchasers of the notes an option to purchase up to an additional $45.0 million aggregate principal amount of the notes. The sale of the notes is expected to close on September 15, 2023, subject to customary closing conditions.
Amphastar Pharmaceuticals Announces Proposed Private Offering of $300.0 Million of Convertible Senior NotesRANCHO CUCAMONGA, CA / ACCESSWIRE / September 11, 2023 / Amphastar Pharmaceuticals, Inc. (
NASDAQAMPH) ("Amphastar") today announced that it intends to offer, subject to market conditions and other factors, $300.0 million aggregate principal amount of convertible senior notes due 2029 (the "notes") in a private placement to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). Amphastar also intends to grant the initial purchasers of the notes an option to purchase up to an additional $45.0 million aggregate principal amount of the notes.
